cilostazol has been researched along with Ischemic Attack, Transient in 23 studies
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 9.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 5.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Patients who participated in the Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardiogenic Stroke Patients Within 48 Hours of Symptom Onset (ADS) trial were included in this study." | 4.31 | Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Cilostazol is known to be a specific type III phosphodiesterase inhibitor, which promotes increased intracellular cAMP levels." | 1.36 | Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. ( Hong, KW; Kim, CD; Lee, DH; Lee, HR; Lee, JH; Lee, JS; Lee, SJ; Lee, WS; Park, SY; Rhim, BY; Shin, HK, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Toyoda, K | 1 |
| Omae, K | 1 |
| Hoshino, H | 1 |
| Uchiyama, S | 1 |
| Kimura, K | 2 |
| Miwa, K | 1 |
| Minematsu, K | 1 |
| Yamaguchi, K | 1 |
| Suda, Y | 1 |
| Toru, S | 1 |
| Kitagawa, K | 1 |
| Ihara, M | 1 |
| Koga, M | 1 |
| Yamaguchi, T | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Tornyos, D | 1 |
| Komócsi, A | 1 |
| Bálint, A | 1 |
| Kupó, P | 1 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Jung, SJ | 1 |
| Shim, SR | 1 |
| Kim, BJ | 2 |
| Jung, JM | 1 |
| Ozawa, T | 1 |
| Fujimoto, S | 1 |
| Aoki, J | 1 |
| Matsuzono, K | 1 |
| Kono, K | 1 |
| Shintani, A | 1 |
| Yoshimura, R | 1 |
| Okada, H | 1 |
| Tanaka, Y | 2 |
| Fujimoto, T | 1 |
| Tomura, N | 1 |
| Terada, T | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Wang, W | 1 |
| Zhang, L | 1 |
| Liu, W | 1 |
| Zhu, Q | 1 |
| Lan, Q | 1 |
| Zhao, J | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Miyamoto, N | 1 |
| Tanaka, R | 2 |
| Shimosawa, T | 1 |
| Yatomi, Y | 1 |
| Fujita, T | 1 |
| Hattori, N | 2 |
| Urabe, T | 3 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Shin, HK | 4 |
| Lee, HR | 1 |
| Lee, DH | 1 |
| Hong, KW | 4 |
| Lee, JH | 4 |
| Park, SY | 3 |
| Lee, SJ | 1 |
| Lee, JS | 2 |
| Lee, WS | 3 |
| Rhim, BY | 1 |
| Kim, CD | 3 |
| Liu, M | 1 |
| Easton, JD | 1 |
| Yamamoto, Y | 1 |
| Ohara, T | 1 |
| Nagakane, Y | 1 |
| Tanaka, E | 1 |
| Morii, F | 1 |
| Koizumi, T | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Heo, SH | 1 |
| Hwang, KJ | 1 |
| Kim, JH | 1 |
| Chang, DI | 1 |
| Liao, JK | 1 |
| Ohara, M | 1 |
| Nagara, Y | 1 |
| Shida, N | 1 |
| Yamashita, Y | 1 |
| Choi, JM | 1 |
| Kim, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for cilostazol and Ischemic Attack, Transient
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Network Meta-Analysis; Pl | 2022 |
Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis.
Topics: Asian People; Brain Ischemia; Cilostazol; Humans; Ischemic Attack, Transient; Network Meta-Analysis; | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; | 2010 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
Topics: Cerebrovascular Disorders; Chronic Disease; Cilostazol; Clinical Trials as Topic; Humans; Ischemic A | 2008 |
1 trial available for cilostazol and Ischemic Attack, Transient
| Article | Year |
|---|---|
Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2022 |
12 other studies available for cilostazol and Ischemic Attack, Transient
| Article | Year |
|---|---|
Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis.
Topics: Blood Pressure; Cilostazol; Humans; Ischemic Attack, Transient; Ischemic Stroke; Recurrence; Stroke | 2023 |
Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2013 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice.
Topics: Adrenomedullin; Animals; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleo | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia.
Topics: Adult Stem Cells; Animals; CA1 Region, Hippocampal; Cell Death; Cell Proliferation; Cilostazol; Dise | 2010 |
Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.
Topics: Animals; Brain Infarction; Bromodeoxyuridine; Cell Count; Cerebral Ventricles; Cilostazol; CREB-Bind | 2010 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients.
Topics: Adult; Aged; Analysis of Variance; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholester | 2013 |
Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis Inducing Factor; CD11 Antigens; Cilostaz | 2007 |
[Marked effectiveness of cilostazol in a case of hemodynamic TIA].
Topics: Bradycardia; Cilostazol; Diagnostic Imaging; Humans; Ischemic Attack, Transient; Male; Middle Aged; | 2007 |
Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Infarction; Cilostazol; Cyc | 2002 |